El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Natera Inc
Cerrado
SectorSalud
198.1 0.66
Resumen
Variación precio
24h
Mínimo
193.24
Máximo
198.19
Ingresos | 135M 47M |
|---|---|
Ventas | 73M 666M |
BPA | 0.36 |
Margen de beneficio | 7.101 |
Empleados | 4,424 |
EBITDA | 41M -35M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +34.49% upside |
Próximas Ganancias | 7 may 2026 |
|---|
Capitalización de Mercado | -1.3B 28B |
|---|---|
Apertura anterior | 197.44 |
Cierre anterior | 198.1 |
Noticias sobre sentimiento de mercado
By Acuity
45%
55%
152 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Natera Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Natera Inc Esperado
Precio Objetivo
By TipRanks
34.49% repunte
Estimación a 12 meses
Media 265.14 USD 34.49%
Máximo 300 USD
Mínimo 215 USD
De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Natera Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
152 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Natera Inc
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
Live chat